Vol. 17/No. 11

This pilot trial is the first of its type to investigate T cell receptor alpha/beta-depleted and CD19-depleted haploidentical stem cell grafts in relapsed/refractory lymphoma patients.

The debate over the confirmation of Robert M. Califf, MD, as FDA commissioner illustrates the need to change the way we talk about whether a medical professional has a "conflict of interest" rather than simply an "association of interest."

Turning around any ship of state, particularly one as large and unwieldy as the oncology research establishment, is always going to be a slow-moving and laborious undertaking.

An elite group of finalists have been recognized for their achievements, talent, and the compassionate care they provide to their patients and families in the 2016 Giants of Cancer Care® recognition program.

Perry Kennedy, PhD, discusses the goals of the RAS Initiative.

Enthusiasm for the MET signaling pathway as a target for anticancer therapy has not waned despite several high-profile failures in multiple indications. This persistence appears to be paying off as promising new data emerge from more recent clinical trials.

The majority of patients with pancreatic adenocarcinoma are diagnosed with late-stage, unresectable tumors, a setting in which combination chemotherapy remains the mainstay.

The RAS family of genes, implicated in more than 30% of human cancers, has proved to be such a difficult molecular driver to target that researchers have considered it "undruggable." A 3-year-old effort by the National Cancer Institute aims to change that—and is making headway.

Researchers are exploring the safety and efficacy of the novel CDK 4/6 inhibitor ribociclib (LEE011) in the phase III MONALEESA- 7 trial.

Shouldn’t the goal of oncologists be to do what is best for their patients, regardless of the currently existing level of evidence and particularly when any timeline for obtaining that "gold standard" evidence will be irrelevant for the patient being cared for today?

The Comprehensive Cancer Center at Wake Forest Baptist Medical Center provides programs and services that are integrated into the ongoing care of patients in order to make professional assistance available easily and seamlessly.

Although advances have been made in imaging techniques for patients with glioblastoma multiforme, new tools are needed to supplement standard imaging sequences.